156.83
1.44 (0.93%)
| Penutupan Terdahulu | 155.39 |
| Buka | 153.21 |
| Jumlah Dagangan | 303,689 |
| Purata Dagangan (3B) | 990,151 |
| Modal Pasaran | 9,211,239,424 |
| Harga / Pendapatan (P/E Ke hadapan) | 2.00 |
| Harga / Jualan (P/S) | 16.03 |
| Harga / Buku (P/B) | 13.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2026 |
| Margin Keuntungan | -30.57% |
| Margin Operasi (TTM) | -19.39% |
| EPS Cair (TTM) | -2.27 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 24.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.09% |
| Nisbah Semasa (MRQ) | 6.49 |
| Aliran Tunai Operasi (OCF TTM) | -45.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.66 M |
| Pulangan Atas Aset (ROA TTM) | -6.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Glaukos Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.17 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.33% |
| % Dimiliki oleh Institusi | 101.71% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |